The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release
Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d
Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel22.4.2026 15:15:00 CEST | Press release
Company underscores leadership use and introduces matched contribution initiative to support verified climate projects. CALGARY, AB / ACCESS Newswire / April 22, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today marked Earth Day by highlighting SkyXero, its mobile application designed to help individuals understand and act on the emissions associated with their air travel. As global travel continues to increase, flight emissions remain one of the least visible and least understood components of individual environmental impact. SkyXero addresses this gap by enabling users to calculate emissions associated with any commercial flight and support verified climate projects such as reforestation, renewable energy, and carbon reduction initiatives. To reinforce its commitment to practical climate accountability, Karbon-X has applied SkyXero internally across its l
DOJO AI Raises $6M to Power Agentic Marketing Platform, Transforming Data Into Business Impact22.4.2026 14:00:00 CEST | Press release
Backed by Armilar and Heartfelt VC, the company serves over 100 customers across the U.S. and U.K., including CoinDesk, Morningstar, Broadvoice, PensionBee, CovertSwarm and Refine Labs LONDON, UK AND LISBON, PORTUGAL / ACCESS Newswire / April 22, 2026 / DOJO AI, the intelligent marketing system that brings a new class of integrated AI to marketing teams, today announced a $6 million seed round at a $30 million valuation. The round was led by Armilar, with participation from Heartfelt VC. The funding will support continued product development and accelerated expansion in the United States. DOJO AI introduces a new paradigm for marketing technology, powering what the industry is beginning to call agentic marketing: a system where AI agents don't just report on performance but take action on it. The platform watches paid and organic campaigns around the clock, audits SEO and Answer Engine Optimization visibility continuously, generates brand-aligned content, and feeds every outcome back i
GoodData Launches Agent Builder for Enterprise AI22.4.2026 12:00:00 CEST | Press release
Enterprises can now deploy governed analytics agents in minutes, with full control over configuration, context, and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 22, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today announced the launch of Agent Builder, a new capability that expands its platform with a dedicated environment for building, configuring, and scaling AI agents across the enterprise. Agent Builder enables organizations to move beyond single-purpose AI assistants and instead deploy multiple, purpose-built analytics agents that can be precisely configured, governed, and scaled across customers, workspaces, and user groups. The launch addresses a growing enterprise challenge: while organizations are rapidly moving from experimentation to production with AI agents, consistent, secure, and scalable deployment across business units remains difficult without significant custom engineering. From Experimentation to Enterprise Scale While most a
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom